In osteosarcoma studies, CD70 has been found to be expressed in a subset of osteosarcoma patients, and CD70 may represent a novel candidate for antibody-based targeted immunotherapy in these patients with CD70 (+) osteosarcoma (Pahl et al., 2015). Here, CD70 is linked to osteosarcoma.